The anti-fibrotic effects of Src inhibition have been reported in several experimental models of fibrotic diseases such as idiopathic pulmonary fibrosis [19, 40], liver fibrosis [20], renal fibrosis [21–23], and systemic sclerosis [18]. Here, SRC is linked to idiopathic pulmonary fibrosis.